845 related articles for article (PubMed ID: 22035756)
21. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
22. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
23. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.
Schmitz R; Renné C; Rosenquist R; Tinguely M; Distler V; Menestrina F; Lestani M; Stankovic T; Austen B; Bräuninger A; Hansmann ML; Küppers R
Leukemia; 2005 Aug; 19(8):1452-8. PubMed ID: 15973455
[TBL] [Abstract][Full Text] [Related]
24. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
25. [Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases].
Huang S; Zheng ZX; Xu Q; Yuan XH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):305-8. PubMed ID: 23985262
[TBL] [Abstract][Full Text] [Related]
26. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
27. Primary large-cell lymphomas of the mediastinum.
Suster S
Semin Diagn Pathol; 1999 Feb; 16(1):51-64. PubMed ID: 10355654
[TBL] [Abstract][Full Text] [Related]
28. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
29. In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Aya-Bonilla C; Camilleri E; Haupt LM; Lea R; Gandhi MK; Griffiths LR
BMC Genomics; 2014 May; 15(1):390. PubMed ID: 24885312
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
[TBL] [Abstract][Full Text] [Related]
32. Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.
Yun J; Kim SJ; Kim JA; Kong JH; Lee SH; Kim K; Ko YH; Kim WS
Acta Haematol; 2010; 123(1):48-54. PubMed ID: 19955711
[TBL] [Abstract][Full Text] [Related]
33. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
34. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
35. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
36. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
39. Burkitt cells on a peripheral blood smear: how to deal with?
Wyrwas M; Michel J; Guibaud I; Lesesve JF; Bénet B
Ann Biol Clin (Paris); 2016 Dec; 74(6):697-703. PubMed ID: 27848920
[TBL] [Abstract][Full Text] [Related]
40. [Advances in the Molecular Diagnosis and Therapy of Relapsed/Refractory Diffuse Large B-cell Lymphoma -Review].
Wang Y; Xia B; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):603-608. PubMed ID: 29665940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
